期刊
ONCOGENE
卷 40, 期 13, 页码 2395-2406出版社
SPRINGERNATURE
DOI: 10.1038/s41388-021-01702-y
关键词
-
资金
- NIH [R01-GM127802]
- DOD-CDMRP-BCRP [W81XWH-16-1-0352]
- Welch Foundation [F1859]
- STORM Therapeutics
- CPRIT [RR160093]
- CPRIT Core Facility Support Grants [RP120348, RP170002]
- DHHS/NCI Cancer Center Support Grant (CCSG) [P30 CA16672]
BCDIN3D plays a crucial role in regulating metabolic pathways in cancer, with a connection to increased glycolysis and reduced glucose metabolism capacity, while also regulating ALDOC expression. This connection may be relevant to breast cancer, obesity, and T2D.
Type II diabetes (T2D) and specific cancers share many risk factors, however, the molecular mechanisms underlying these connections are often not well-understood. BCDIN3D is an RNA modifying enzyme that methylates specific precursor microRNAs and tRNA(His). In addition to breast cancer, BCDIN3D may also be linked to metabolism, as its gene locus is associated with obesity and T2D. In order to uncover metabolic pathways regulated by BCDIN3D in cancer, we performed an unbiased analysis of the metabolome, transcriptome, and proteome of breast cancer cells depleted for BCDIN3D. Intersection of these analyses showed that BCDIN3D-depleted cells have increased levels of Fructose 1,6 Bisphosphate (F1,6-BP), the last six-carbon glycolytic intermediate accompanied by reduced glycolytic capacity. We further show that elevated F1,6-BP is due to downregulation of Aldolase C (ALDOC), an enzyme that cleaves F1,6-BP mainly in the brain, but whose high expression/amplification is associated with poor prognosis in breast cancer. BCDIN3D regulates ALDOC through a non-canonical mechanism involving the crucial let-7 microRNA family and its target site on the 3 ' UTR of ALDOC. Overall, our results reveal an important connection between BCDIN3D, let-7 and glycolysis that may be relevant to breast cancer, obesity, and T2D.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据